These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 23258564)

  • 21. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.
    Ding H; Helguera G; Rodríguez JA; Markman J; Luria-Pérez R; Gangalum P; Portilla-Arias J; Inoue S; Daniels-Wells TR; Black K; Holler E; Penichet ML; Ljubimova JY
    J Control Release; 2013 Nov; 171(3):322-9. PubMed ID: 23770212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy.
    Mårlind J; Kaspar M; Trachsel E; Sommavilla R; Hindle S; Bacci C; Giovannoni L; Neri D
    Clin Cancer Res; 2008 Oct; 14(20):6515-24. PubMed ID: 18927291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3.
    Jia LT; Zhang LH; Yu CJ; Zhao J; Xu YM; Gui JH; Jin M; Ji ZL; Wen WH; Wang CJ; Chen SY; Yang AG
    Cancer Res; 2003 Jun; 63(12):3257-62. PubMed ID: 12810656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potent inhibition of human gastric cancer by HER2-directed induction of apoptosis with anti-HER2 antibody and caspase-3 fusion protein.
    Zhang DX; Zhao PT; Xia L; Liu LL; Liang J; Zhai HH; Zhang HB; Guo XG; Wu KC; Xu YM; Jia LT; Yang AG; Chen SY; Fan DM
    Gut; 2010 Mar; 59(3):292-9. PubMed ID: 19951902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
    Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
    Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
    O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Expression and Characterization of Single-chain Fv-Fc Fusion Protein against Human P185(erbB2)].
    Xie ZG; Guo N; Shi M; Feng JN; Yu M; Sun YX; Shen BF
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Apr; 35(4):371-4. PubMed ID: 12673393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
    Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
    Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
    Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vesicular stomatitis virus expressing a chimeric Sindbis glycoprotein containing an Fc antibody binding domain targets to Her2/neu overexpressing breast cancer cells.
    Bergman I; Whitaker-Dowling P; Gao Y; Griffin JA; Watkins SC
    Virology; 2003 Nov; 316(2):337-47. PubMed ID: 14644615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel approach to tumor suppression with microencapsulated recombinant cells.
    Cirone P; Bourgeois JM; Austin RC; Chang PL
    Hum Gene Ther; 2002 Jul; 13(10):1157-66. PubMed ID: 12133269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addition of anti-neu antibody to local irradiation can improve tumor-bearing BALB/c mouse survival through immune-mediated mechanisms.
    Ma SY; Song H; Park JH; Choi JH; Kim JH; Kim KH; Park S; Park DH; Kang MS; Kwak M; Fu YX; Choi I; Cho H; Park S
    Radiat Res; 2015 Mar; 183(3):271-8. PubMed ID: 25706775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid purification of a new humanized single-chain Fv antibody/human interleukin-2 fusion protein reactive against HER2 receptor.
    Zhang WY; Yip TC; Kwok CS
    Acta Biochim Biophys Sin (Shanghai); 2004 Oct; 36(10):707-12. PubMed ID: 15483752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.
    Wang L; He Y; Zhang G; Ma J; Liu C; He W; Wang W; Han H; Boruah BM; Gao B
    PLoS One; 2013; 8(9):e75589. PubMed ID: 24086580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Targeted Delivery of Quantum Dots to HER2-Expressing Tumor Using Recombinant Antibodies].
    Balalaeva IV; Zdobnova TA; Sokolova EA; Deyev SM
    Bioorg Khim; 2015; 41(5):599-605. PubMed ID: 26762098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FcUni-RLuc: an engineered Renilla luciferase with Fc binding ability and light emission activity.
    Farzannia A; Roghanian R; Zarkesh-Esfahani SH; Nazari M; Emamzadeh R
    Analyst; 2015 Mar; 140(5):1438-41. PubMed ID: 25622753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a novel small antibody that retains specificity for tumor targeting.
    Zhen ZP; Zhang J; Zhang SY
    J Exp Clin Cancer Res; 2009 Apr; 28(1):59. PubMed ID: 19405947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.